Story perspectives

Bristol Myers Squibb Acquires Orbital for $1.5 Billion

10/11/2025

Summary

Bristol Myers Acquires Orbital

Bristol Myers Squibb (BMS) has finalized a $1.5 billion acquisition of Orbital Therapeutics, amid Takeda's exit.
The deal includes OTX-201, a preclinical CAR T-cell therapy that targets autoimmune diseases and uses the patient's cells to produce therapeutic constructs.
BMS will leverage Orbital's AI-driven RNA platform for broader uses, including cancer treatments and RNA vaccines.
Analysts from BMO Capital Markets cautioned that broader use may face logistical challenges.

Summary

Bristol Myers Acquires RNA Innovator

Bristol Myers Squibb (BMS) announced it will acquire Orbital Therapeutics for $1.5 billion to strengthen its cell therapy portfolio.
Orbital Therapeutics, based in Cambridge, Massachusetts, develops RNA medicines that reprogram the immune system in vivo.
The deal includes OTX-201, an investigational CAR T-cell therapy targeting autoimmune diseases.
The deal will proceed under customary closing conditions.

1 of 2

Bristol Myers Acquires Orbital

Bristol Myers Squibb (BMS) has finalized a $1.5 billion acquisition of Orbital Therapeutics, amid Takeda's exit.
The deal includes OTX-201, a preclinical CAR T-cell therapy that targets autoimmune diseases and uses the patient's cells to produce therapeutic constructs.
BMS will leverage Orbital's AI-driven RNA platform for broader uses, including cancer treatments and RNA vaccines.
Analysts from BMO Capital Markets cautioned that broader use may face logistical challenges.

1 / 2